1637 related articles for article (PubMed ID: 29771163)
1. Review of Saccharomyces boulardii as a treatment option in IBD.
Sivananthan K; Petersen AM
Immunopharmacol Immunotoxicol; 2018 Dec; 40(6):465-475. PubMed ID: 29771163
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of probiotics in inflammatory bowel disease.
Cain AM; Karpa KD
Altern Ther Health Med; 2011; 17(1):72-9. PubMed ID: 21614946
[TBL] [Abstract][Full Text] [Related]
3. Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review.
Ganji-Arjenaki M; Rafieian-Kopaei M
J Cell Physiol; 2018 Mar; 233(3):2091-2103. PubMed ID: 28294322
[TBL] [Abstract][Full Text] [Related]
4. Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management.
Kerman DH; Deshpande AR
Postgrad Med; 2014 Jul; 126(4):7-19. PubMed ID: 25141239
[TBL] [Abstract][Full Text] [Related]
5. Prebiotics and Probiotics in Inflammatory Bowel Disease: Where are we now and where are we going?
Naseer M; Poola S; Ali S; Samiullah S; Tahan V
Curr Clin Pharmacol; 2020; 15(3):216-233. PubMed ID: 32164516
[TBL] [Abstract][Full Text] [Related]
6. Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy.
Fedorak RN; Ismond KP
Dig Dis; 2016; 34(1-2):112-21. PubMed ID: 26982586
[TBL] [Abstract][Full Text] [Related]
7. Rationale for probiotic and antibiotic treatment strategies in inflammatory bowel diseases.
Schultz M; Schölmerich J; Rath HC
Dig Dis; 2003; 21(2):105-28. PubMed ID: 14571109
[TBL] [Abstract][Full Text] [Related]
8. Antibiotics and probiotics in treatment of inflammatory bowel disease.
Gionchetti P; Rizzello F; Lammers KM; Morselli C; Sollazzi L; Davies S; Tambasco R; Calabrese C; Campieri M
World J Gastroenterol; 2006 Jun; 12(21):3306-13. PubMed ID: 16733845
[TBL] [Abstract][Full Text] [Related]
9. Saccharomyces boulardii does not prevent relapse of Crohn's disease.
Bourreille A; Cadiot G; Le Dreau G; Laharie D; Beaugerie L; Dupas JL; Marteau P; Rampal P; Moyse D; Saleh A; Le Guern ME; Galmiche JP;
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):982-7. PubMed ID: 23466709
[TBL] [Abstract][Full Text] [Related]
10. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials.
Hedin C; Whelan K; Lindsay JO
Proc Nutr Soc; 2007 Aug; 66(3):307-15. PubMed ID: 17637082
[TBL] [Abstract][Full Text] [Related]
11. A pilot trial of Saccharomyces boulardii in ulcerative colitis.
Guslandi M; Giollo P; Testoni PA
Eur J Gastroenterol Hepatol; 2003 Jun; 15(6):697-8. PubMed ID: 12840682
[TBL] [Abstract][Full Text] [Related]
12. Review article: fungal alterations in inflammatory bowel diseases.
Lam S; Zuo T; Ho M; Chan FKL; Chan PKS; Ng SC
Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1159-1171. PubMed ID: 31648369
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis.
Thomas S; Metzke D; Schmitz J; Dörffel Y; Baumgart DC
Am J Physiol Gastrointest Liver Physiol; 2011 Dec; 301(6):G1083-92. PubMed ID: 21903765
[TBL] [Abstract][Full Text] [Related]
14. The gut microbiota in inflammatory bowel disease.
Macfarlane GT; Blackett KL; Nakayama T; Steed H; Macfarlane S
Curr Pharm Des; 2009; 15(13):1528-36. PubMed ID: 19442170
[TBL] [Abstract][Full Text] [Related]
15. Probiotics and prebiotics in Crohn's disease therapies.
Lichtenstein L; Avni-Biron I; Ben-Bassat O
Best Pract Res Clin Gastroenterol; 2016 Feb; 30(1):81-8. PubMed ID: 27048899
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
Pearce CB; Duncan HD; Timmis L; Green JR
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):439-43. PubMed ID: 10783998
[TBL] [Abstract][Full Text] [Related]
17. Probiotics and Their Use in Inflammatory Bowel Disease.
Amer M; Nadeem M; Nazir SUR; Fakhar M; Abid F; Ain QU; Asif E
Altern Ther Health Med; 2018 May; 24(3):16-23. PubMed ID: 29135456
[TBL] [Abstract][Full Text] [Related]
18. Role of Probiotics in Crohn's Disease and in Pouchitis.
Guslandi M
J Clin Gastroenterol; 2015; 49 Suppl 1():S46-9. PubMed ID: 26447964
[TBL] [Abstract][Full Text] [Related]
19. Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP; Li JS; Ouyang Q; Hu RW; Zhang Y; Li HY
Cochrane Database Syst Rev; 2014 Oct; (10):CD007744. PubMed ID: 25340915
[TBL] [Abstract][Full Text] [Related]
20. Clinical usefulness of probiotics in inflammatory bowel diseases.
Mach T
J Physiol Pharmacol; 2006 Nov; 57 Suppl 9():23-33. PubMed ID: 17242485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
